Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO

NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. ( STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that positive data from the SL-701 and SL-801 clinical trials were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

The presentations are available on Stemline’s website (www.stemline.com) under the Scientific Presentations tab.